title: Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy.
abstract: Plasma cell leukemia (PCL) is a rare variant of multiple myeloma, which is very aggressive and resistant to chemotherapy. We report a case of PCL successfully treated with syngeneic peripheral blood stem cell transplantation followed by low-dose thalidomide. As of March 2009, the patient has maintained CR for 39 months posttransplant. The clinical course of the present case suggests that autologous stem cell transplantation using a graft with reduced contamination of malignant cells followed by low-dose thalidomide maintenance therapy may improve the PCL treatment outcome.
authors.affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Abe
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tohmiya
authors.forename: Yoko
authors.initials: Y
authors.lastname: Okitsu
authors.forename: Hiroto
authors.initials: H
authors.lastname: Ohguchi
authors.forename: Katsura
authors.initials: K
authors.lastname: Kohata
authors.forename: Joji
authors.initials: J
authors.lastname: Yamamoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Onishi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ishizawa
authors.forename: Junichi
authors.initials: J
authors.lastname: Kameoka
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D008297:Male; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage*; D014185:Transplantation, Isogeneic / Q000379:methods
chemical_list: D013792:Thalidomide